

OVERVIEW

Animate Biosciences is developing a new class of peptide therapeutics designed to restore healthy tissue repair by reprogramming our body's healing response. By integrating insights from regenerative biology with AI and modern peptide chemistry, Animate designs multi-mechanistic drugs that address healing across organs. Animate's platform is rooted in breakthrough research on super-regenerative species led by Harvard professor and co-founder Dr. Jessica Whited.

UNMET NEED = OPPORTUNITY

Pathological healing underlies many chronic and progressive diseases, contributing to >45% of global mortality.

Current therapies are organ-specific, poorly tolerated, and primarily slow disease progression rather than reverse underlying pathology.

The pathological remodeling market represents a \$200B+ market opportunity, with significant demand for safer, disease-modifying therapies.

ANIMATE PLATFORM & LEAD PROGRAMS

Platform & Technology

Animate's proprietary discovery platform combines:

- Multi-omic datasets derived from super-regenerative species (i.e. axolotl)
- AI-driven peptide design to rapidly identify novel, bioactive sequences
- Advanced solid-phase peptide synthesis enabling rapid design-to-test cycles, often under two weeks

This integrated approach enables rapid discovery of short peptides with multi-mechanistic activity & favorable safety profiles.



Multi-Organ Solution

Animate's lead peptide programs have demonstrated robust anti-inflammatory and anti-fibrotic activity across multiple human cell systems, including lung, heart, liver, and skin models. These peptides suppress key inflammation and fibrotic markers such as α SMA, Col1A1, IL-6, and TNF α .



Effective in Preclinical Animal Models

Animate's lead peptide has demonstrated robust, consistent efficacy across four organ systems, including lung, heart, liver, and skin, with significant reductions in scarring, inflammation, and tissue damage alongside improvements in functional repair.



Protected Intellectual Property

Animate's growing pipeline is protected by three patent filings covering platform technology, composition of matter, and methods of use.

STRATEGY

Animate is raising \$3 million to advance IND-enabling studies and initiate Phase I clinical trials, initially targeting an orphan pulmonary disease indication. Successful clinical validation will support rapid expansion into broader systemic diseases.

CONCLUSION

Animate Biosciences is pioneering a new therapeutic paradigm, restoring healthy healing as a foundation for treating chronic disease by:

- A differentiated AI-driven platform
- Compelling multi-organ preclinical data
- A focused, capital-efficient clinical strategy

Animate is positioned to deliver first-in-class regenerative therapeutics and create substantial clinical and commercial value.

LEADERSHIP

Led by a highly experienced team spanning biologics development, regenerative biology, and company building.

Peter Licari, PhD, MBA (Chief Executive Officer & Co-Founder)

Biochemical engineer with over 3 decades of experience in leadership roles at Merck, BASF, Kosan, Solazyme, and Eat JUST. His experience includes work on approved drug products such as Humira[®] and VAQTA[®].

Jessica Whited, PhD (Chief Scientific Officer & Co-Founder)

Associate professor at Harvard University and a global leader in regenerative species biology.

Jonathan Wolfson, JD, MBA (Executive Chair & Co-Founder)

Serial entrepreneur with a track record of company creation, commercialization, and public exits, including Solazyme's IPO.